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Abstract
The measurement of ovarian volume has been shown to be a useful indirect indicator of the ovarian reserve
in women of reproductive age, in the diagnosis and management of a number of disorders of puberty and
adult reproductive function, and is under investigation as a screening tool for ovarian cancer. To date
there is no normative model of ovarian volume throughout life. By searching the published literature for
ovarian volume in healthy females, and using our own data from multiple sources (combined n = 59,994)
we have generated and robustly validated the first model of ovarian volume from conception to 82 years
of age. This model shows that 69% of the variation in ovarian volume is due to age alone. We have shown
that in the average case ovarian volume rises from 0.7 mL (95% CI 0.4 – 1.1 mL) at 2 years of age to a
peak of 7.7 mL (95% CI 6.5 – 9.2 mL) at 20 years of age with a subsequent decline to about 2.8mL (95%
CI 2.7 – 2.9 mL) at the menopause and smaller volumes thereafter. Our model allows us to generate
normal values and ranges for ovarian volume throughout life. This is the first validated normative model
of ovarian volume from conception to old age; it will be of use in the diagnosis and management of a
number of diverse gynaecological and reproductive conditions in females from birth to menopause and
beyond.
Introduction
The main functions of the ovary are to provide gametes and sex steroids to allow and support the
establishment of pregnancy, and act as a repository for the non-growing follicles (NGFs) that allow this
process to take place over several decades. The main constituents of the ovary are therefore its follicle
endowment (both growing and non-growing), and the stromal tissues that support these functions. The
human ovary establishes its complete complement of non-growing follicles during fetal life, and after
birth there is a continuous process of recruitment until menopause at an average age of 50-51 years,
when fewer than one thousand remain [1–3]. There is a wide variation in the age at menopause between
individuals [4, 5] and it is thought that this is due in large part to variations in the initial endowment of
NGFs [1]. Currently, clinical assessment is unable to assess reliably the number of NGFs, or their rate of
loss or activation.
Ovarian volume is one of several putative biomarkers of the ovarian reserve, others include serum anti-
Mu¨llerian Hormone (AMH), and antral follicle count (AFC) which have have been shown to have clinical
utility in the assessment of women with subfertility [6]. Ovarian volume is currently one of the diagnostic
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2criteria for the most common endocrinopathy in women (polycystic ovary syndrome; PCOS) [7, 8] and
may be of value in screening for ovarian cancer [9]. We have shown a strong and positive correlation
between ovarian volume and NGF population in the human ovary for ages 25-51 years [10], but there is
only sparse information available on ovarian volume in healthy young girls and women [11]. A greater
understanding of the changes in ovarian volume throughout life are likely to be helpful in the diagnosis
and treatment of many disorders in gynaecology and reproductive medicine [12].
The data on ovarian volume in young girls is limited due to the lack of an easy non-invasive method
of imaging the ovaries accurately. Much of the data that is published is in girls with abnormalities in
pubertal development and so does not reflect the healthy population [13, 14]. In the adult woman the
advent of transvaginal ultrasound as a routine gynaecological technique has led to a large source of data
on ovarian volume in healthy women [15]. To date no single study has examined ovarian volume across
the lifespan in healthy females. The aim of this study is to develop a validated model of ovarian volume
in healthy females from conception throughout life from data aggregation from multiple sources.
Figure 1. The validated model of log-adjusted ovarian volume throughout life. The r2
coefficient of determination indicates that 69% of the variation in human ovarian volumes is due to age
alone. Colour bands indicate ranges within ±1 standard deviation from mean, within ±1 and ±2
standard deviations, and outside 2 standard deviations.
Results
The validated model is a degree 14 polynomial of the form
log10(V olume + 1) = c0 + c1age + c2age
2 + . . . + c13age
14
3with coefficients ci given in Table 1, and relationship to the data given in Figure 1. The model has
coefficient of determination r2 = 0.69 indicating that around 69% of the variation in ovarian volumes
throughout life is due to age alone. The residual plot (Figure 7) shows a distribution close to the ideal
Gaussian curve (r2 = 0.993), this coefficient of determination being higher than that for three other
possible curves for these residuals. Moreover, the proportions of residuals within one, two and three
standard deviations (respectively 71%, 96% and 99%) are close to the expected values for data with a
Gaussian distribution (respectively 68%, 95% and 99%). Figure 6 is an exemplar of the 5-fold validation
process in which a model is chosen that neither overfits nor underfits the underlying dataset.
Table 1. Coefficients for the validated model
i Coefficient ci Standard Error T Value 95% Conf Lim 95% Conf Lim
0 8.92E-02 8.00E-03 11.2 -1.24E-02 1.91E-01
1 1.10E-01 8.28E-03 13.3 5.22E-03 2.16E-01
2 -3.05E-02 5.92E-03 -5.2 -1.06E-01 4.47E-02
3 5.09E-03 1.63E-03 3.1 -1.56E-02 2.58E-02
4 -4.35E-04 2.34E-04 -1.9 -3.40E-03 2.53E-03
5 2.49E-05 2.03E-05 1.2 -2.33E-04 2.83E-04
6 -1.23E-06 1.15E-06 -1.1 -1.59E-05 1.34E-05
7 5.43E-08 4.49E-08 1.2 -5.17E-07 6.25E-07
8 -1.89E-09 1.23E-09 -1.5 -1.75E-08 1.38E-08
9 4.66E-11 2.40E-11 1.9 -2.59E-10 3.52E-10
10 -7.87E-13 3.31E-13 -2.4 -4.99E-12 3.42E-12
11 8.87E-15 3.15E-15 2.8 -3.12E-14 4.89E-14
12 -6.36E-17 1.97E-17 -3.2 -3.14E-16 1.87E-16
13 2.63E-19 7.32E-20 3.6 -6.67E-19 1.19E-18
14 -4.77E-22 1.22E-22 -3.9 -2.02E-21 1.07E-21
Coefficients for the validated normative model of human ovarian volume throughout life. Each
coefficient value is reported together with estimates of the standard error, T-statistic and 95%
confidence limits for the value.
The log-unadjusted predictive normative model is shown in Figure 2. This shows the mean volume
per ovary in millilitres (mL) for the healthy human population, together with prediction intervals at ±1
and ±2 standard deviations (SD). Approximately 68% of ovarian volumes are expected to lie within ±1
SD of the mean; approximately 95% within ±2 SD of the mean. Mean and normative ranges for ovarian
volumes are given for ages from birth to 50 years in Table 2. Our model shows that in the average case
ovarian volume rises from 0.7 mL (95% CI 0.4 – 1.1 mL) at 2 years of age to a peak of 7.7 mL (95% CI
6.5 – 9.2 mL) at 20 years of age and declines throughout life to about 2.8mL (95% CI 2.7 – 2.9 mL) at
the menopause.
The data do not support the notion of two distinct populations, PCOS and non-PCOS, giving a
bimodal distribution of ovarian volumes at a given age. Model residual plots for ages up to 10 years are
approximately normally distributed (Figure 3). Model residual plots for ages 10 through 30 years (Figure
4) and over 30 years (Figure 5) are close to an ideal normal distribution.
When the data is censored to remove 444 values over 10 mL, in line with the Rotterdam criteria for
PCOS [7, 8], the model changes slightly both in qualitative and quantitative terms, with a coefficient of
determination r2 = 0.69 for both models. The censored-data model is the same as the full-data model
for young and old ages – average volume 0.7 mL (95% CI 0.4 – 1.1 mL) at 2 years and 2.8mL (95%
CI 2.7 – 2.9 mL) at age 50 years. The censored-data model has a lower peak predicted ovarian volume
in the average case, 6.4mL (95% CI 5.4 – 7.6 mL), with the peak occurring one year later at 21 years.
4Figure 2. The normative validated model of ovarian volume throughout life. The red line is
predicted mean ovarian volume in millilitres for any age. Colour bands indicate ranges within ±1
standard deviation from mean, within ±1 and ±2 standard deviations, and outside 2 standard
deviations.
This lower peak is outside the 95% confidence interval 6.5 – 9.2 mL for the full model peak, suggesting
a statistically significant difference between the two peak values.
Discussion
We have described and validated the first normative model that describes ovarian volume in healthy
females from conception to 82 years. The model has a coefficient of determination r2 = 0.69 indicating
that 69% of the variation in ovarian volumes throughout life is due to age alone. Ovarian volume rises
through childhood and adolescence and is maximal in the average woman at 20 years of age, declining
thereafter towards the menopause and beyond.
Transvaginal ultrasound evaluation has been used as an indirect assessment of ovarian reserve in
adult sexually active females [16]. We have previously shown a strong positive correlation (r = 0.89)
between NGF numbers and ovarian volume from ages 25 to 51 years [10], i.e. during the time that
both are declining. Our normative model now adds to this by showing a steady rise in ovarian volume
from birth (Figure 2) with a modest acceleration around the onset of puberty (age 9–10 years). The
major contribution to ovarian volume before puberty is likely to be stromal growth; while small antral
follicles are present in the ovaries of prepubertal girls of all ages [17], larger follicles are not found while
serum gonadotrophin concentrations remain low. After menarche and the onset of ovulation the major
5Table 2. Ovarian volumes by age
Age 3SD below 2SD below 1SD below Mean ovarian vol. 1SD above 2SD above 3SD above
0 0.0 0.0 0.0 0.2 0.5 0.8 1.3
2 0.0 0.1 0.4 0.7 1.0 1.5 2.1
4 0.0 0.3 0.6 0.9 1.3 1.8 2.5
6 0.2 0.5 0.8 1.2 1.7 2.3 3.0
8 0.5 0.8 1.2 1.7 2.3 3.0 3.9
10 0.9 1.3 1.9 2.5 3.3 4.3 5.4
12 1.5 2.1 2.8 3.7 4.7 6.0 7.5
14 2.3 3.0 3.9 5.0 6.4 8.0 10.1
16 3.0 3.9 5.0 6.4 8.0 10.0 12.5
18 3.5 4.5 5.8 7.3 9.2 11.4 14.2
20 3.7 4.8 6.1 7.7 9.6 12.0 15.0
22 3.7 4.7 6.0 7.6 9.5 11.9 14.7
24 3.5 4.5 5.7 7.2 9.0 11.2 14.0
26 3.2 4.1 5.3 6.7 8.4 10.5 13.1
28 3.0 3.9 4.9 6.3 7.9 9.9 12.4
30 2.8 3.7 4.7 6.0 7.6 9.5 11.9
32 2.8 3.6 4.6 5.9 7.5 9.4 11.7
34 2.7 3.6 4.6 5.9 7.4 9.3 11.6
36 2.7 3.6 4.6 5.8 7.4 9.2 11.5
38 2.6 3.5 4.5 5.7 7.2 9.0 11.3
40 2.5 3.3 4.2 5.4 6.8 8.6 10.7
42 2.2 3.0 3.8 4.9 6.3 7.9 9.9
44 1.9 2.6 3.4 4.4 5.6 7.1 8.9
46 1.6 2.2 2.9 3.8 4.9 6.2 7.8
48 1.3 1.8 2.5 3.3 4.2 5.4 6.8
50 1.1 1.6 2.1 2.8 3.7 4.7 6.0
Normative values for ovarian volumes in millilitres for ages from birth through 50 years at two year
stages. SD below and above refer to standard deviations below and above mean predicted volume.
contribution to changing ovarian volume is likely to be the number and size of the antral follicles present.
Human growth in childhood is described as three additive and partly superimposed components:
infancy, childhood and puberty [18]. Each component appears to be controlled by distinct biological
mechanisms. The infancy component is largely nutrition dependent, the childhood component is mostly
dependent on growth hormone (GH) and the pubertal component depends on the synergism between sex
steroids and GH. The slow rise in ovarian volume throughout mid-childhood (Figures 1 and 2) followed by
an increase in ovarian volume during the pubertal years suggests that GH, in addition to sex steroids, may
have an important role in determining ovarian size (and possibly function) in the early and late childhood
years. A role for GH in determining ovarian size and volume during childhood and puberty is suggested
by data from Bridges et al. 1993 who studied girls with growth disorders: GH insufficiency, skeletal
dysplasia, and tall stature [13]. Total ovarian volume of untreated GH-insufficient girls was significantly
less than that of GH-insufficient girls on GH treatment, girls with skeletal dysplasia on GH treatment,
and girls with tall stature. They also found that tall girls had significantly greater ovarian volume than
either of the GH-treated groups.
The measurement of ovarian volume has been found to be useful in a wide range of disorders in
children and young females. Measurement of ovarian volume is an accurate diagnostic tool for adolescent
6Figure 3. Model residuals for ages up to 10 years. Residuals are the squared differences between
data values and predicted values for that age.
girls with irregular menses. In the majority of these girls, enlarged ovaries are associated with polycystic
ovary syndrome (PCOS) [19] and ovarian volume is part of the diagnostic criteria for that condition [7,8].
Recent results suggest that antral follicle counts have better discriminatory performance than ovarian
volume [20]. We therefore censored our dataset to exclude all women with ovarian volume greater than
10mL. As the descriptions of subjects included in the original references varies, women with PCOS – or
asymptomatic women whose ovaries had polycystic ovary morphology (PCOM) may have been included.
In the largest data source, PCOS was not actively excluded: “ ...Patients with a solid or cystic ovarian
ovarian tumor detected by sonography were excluded from this investigation since the purpose of this
study was to determine normal ovarian volume...” [15]. Excluding these data points resulted in a reduction
in the peak average ovarian volume, as would be expected, and a slight increase in the age at which the
peak was reached. Importantly, our analysis does not not shed light on the validity of the criteria for the
diagnosis of PCOS.
Girls with precocious puberty have significantly increased ovarian volumes compared with a normal
population [21] and ovarian volume has been proposed as a useful discriminator between central precocious
puberty and premature thelarche [22]. Furthermore, measurement of ovarian volume is a useful index
with which to assess the efficacy of treatment of central precocious puberty with GnRH analogues [23].
The role of transvaginal USS as a screening test for ovarian cancer remains an important area of
study [9, 15, 24] and transvaginal USS has an established role in the assessment and management of
subfertility and in-vitro fertilization (IVF) in adult women [12, 25]. It remains difficult to assess ovarian
reserve in adolescents and young women with cancer due to the considerable age-related changes in the
various markers available. The measurement of ovarian volume in addition to AMH may help predict
7Figure 4. Model residuals for ages between 10 and 30 years. Residuals are the squared
differences between data values and predicted values for that age.
which young women are at particular risk of premature ovarian insufficiency following cancer treatment
and who may therefore benefit from fertility preservation techniques [26,27].
Our model is derived from data from multiple sources of the measurement of ovarian volume in
otherwise healthy females. This is both a strength and a weakness of the study. The strength is that
the measuring errors, both underestimating and overestimating ovarian volume, are likely to be negated
as any bias is unlikely to be always in the same direction for each data source. The weakness is the
heterogeneity of the values obtained from diverse sources. We cannot be certain that the measurement
of ovarian volume by abdominal ultrasound, which is often difficult in young children, is as accurate as
measurement by transvaginal ultrasound in older females [28]. Similarly measurements taken at MRI
may be different from those obtained by weighing the ovary following oophorectomy and calculating the
volume from weight. The largest data source consists of values imputed from a very large data source
obtained by transvaginal ultrasound as part of a screening programme for ovarian cancer [15].
This study excluded patients with a solid or cystic ovarian tumor detected by sonography, but not
patients with polycystic ovary morphology.
Our normative model of ovarian volume using data derived from multiple data sources and different
methods of assessment overcomes the weakness of other studies in which only one imaging modality is
used, because any potential bias in one direction is likely to be negated.
We have shown that in the average case ovarian volume rises from 0.7 mL (95% CI 0.4 – 1.1 mL) at
2 years of age to a peak of 7.7 (95% CI 6.5 – 9.2 mL) mL at 20 years of age and declines throughout
later life to about 2.8 mL (95% CI 2.7 – 2.9 mL) at the menopause. This is the first validated normative
model of ovarian volume from conception to old age; it will be of use in the diagnosis and management
8of a number of diverse gynaecological and reproductive conditions in females from birth to menopause
and beyond.
Figure 5. Model residuals for ages over 30 years. Residuals are the squared differences between
data values and predicted values for that age.
Materials and Methods
The research methodology used both for data acquisition and data analysis closely follows that used to
derive a validated normative model for the level of anti-Mu¨llerian hormone (AMH) found in the blood of
healthy human females for ages from conception to menopause [29,30].
Ethics statement
Permission to perform basic science studies on the ovarian material retrieved in Denmark was given
by the Minister of Health in Denmark and by the Committee on Biomedical Research Ethics of the
Capital Region on 21st September 2011 (protocol number H-2-2011-044). Written informed consent for
the original human work that produced the tissue samples was obtained, and all data were anonymised
prior to analysis.
Data acquisition
The data for this study (Table 3) come from three sources: our own measurements of ovarian volume,
imputation from the large-scale study by Pavlik et al. [15] as described in [10], and publications in the
9Table 3. Ovarian volume data sources
Study Statistics
Ref. First author Year No. ovaries Min. age Max. age Median age
[10] Kelsey 2012 58,227 24.0 85.0 55.0
[33] Badouraki 2008 99 1.0 11.0 7.0
[34] Razzaghy-Azar 2011 480 6.1 13.6 7.0
[35] Seth 2002 92 8.0 15.0 11.5
[36] Holm 1995 165 5.9 25.4 13.9
[37] Ziereisen 2001 122 2.0 15.7 9.3
[38] Griffin 1995 153 0.0 14.9 5.8
[14] Stanhope 1985 40 0.8 13.7 7.3
* Wilkinson 2012 98 2.0 16.7 13
* Andersen 2012 384 0.5 39.8 27.5
[39] Sforza 2004 25 -0.5 0.7 0.0
[40] Simkins 1932 39 -0.7 14 0.3
Overall 59,954 -0.7 85.0 55.0
The year column refers to the year of publication; * denotes our own unpublished data.
scientific literature. Taken as a single dataset, it approximates the healthy population in terms of ovarian
volume, for ages ranging from mid-term fetal to postmenopausal.
We included data from two unpublished sources. Firstly, a detailed assessment of 300 MRI exami-
nations in children without known endocrine, chromosomal or oncological conditions that included the
pelvis, yielded 49 pairs of ovaries where both ovaries were visualized and measurable in three dimensions
(median age 13 years, range 2 to 16.7 years). Ovarian volumes were calculated using the prolate ellipsoid
approximation formula a × b × c × pi6 . Secondly, a further 384 ovaries (median age 27.5 years, range 0.5
to 39.8 years) were weighed before cryopreservation at the University Hospital of Copenhagen. Subjects
were known to have non-ovarian cancer; subjects who had received chemotherapy were excluded. Ovarian
volume was estimated using the published conversion factor for ovarian tissue density: 1.00 g/mL [31].
Summary statistics were extracted from Pavlik et al. [15] for ages 24–85 years. Repeated (10-fold)
parametric bootstrapping [32] was used to simulate datapoints from the published distributions to obtain
a single dataset (n = 58, 255) that accurately reproduces the published results.
In order to obtain data from the existing literature with emphasis on volumes earlier in life than the
24 years minimum age reported in Pavlik et al. [15] studies of ovarian volume in normal, healthy girls
were identified using Medline and PubMed searches using the search terms Ovary, Child, Ovarian size/
volume, Normal, Healthy and Neonatal. The references of these identified studies were then reviewed,
and any other relevant research papers were extracted. Papers were included if they contained ovarian
volume results for healthy, normal girls with no ovarian or endocrinological abnormalities, so as to isolate
data that approximate the healthy human population. Abstracts of 37 studies were identified via this
method.
After analysis of the full papers, studies were excluded if either (i) the results consisted purely of
descriptive statistics, or (ii) subjects were classified by pubertal stage rather than age. Of the remaining
nine studies, seven contained data measured by trans-abdominal ultrasound and plotted in graphs [14,
33–38] while two contained tabular data (with fetal/neonatal ovaries extracted and measured/sliced to
calculate volumes) [39, 40]. The data was extracted from the graphs (n = 1, 151) using Plot Digitizer
software [41], and combined with the tabular data (n = 64). Ovarian volumes were standardised to the
prolate ellipsoid approximation formula a× b× c× pi6 since some studies used the variation a× b× c× 12 .
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Data analysis
Zero volume values at conception were added to the combined dataset (Table 3), in order to force
models through the only known volume at any age. Since variability increases with ovarian volume, we
log-adjusted the data (after adding one to each value so that zero volume on a chart represents zero
ovarian volume). We then fitted 310 mathematical models to the training data using TableCurve-2D
(Systat Software Inc., San Jose, California, USA), and ranked the results by coefficient of determination,
r2. Each model defines a generic type of curve and has parameters which, when instantiated gives a
specific curve of that type. For each model we calculated values for the parameters that maximise the
r2 coefficient. The Levenberg-Marquardt non-linear curve-fitting algorithm was used throughout, with
convergence to 6 significant figures after a maximum of 1,500 iterations. For each candidate model, the
mean square error and r2 were calculated after removing the artificial zero values at conception.
Figure 6. Model validation analysis. The tradeoff between overfit and underfit for one of the five
cross-validation data splits. Models with degree less than 11 are unsuitable due to low r2; models with
degree greater than 17 are unsuitable due to larger differences between test and training mean-squared
errors. The degree 14 model is optimal.
The best performing family of models were high precision polynomials. 5-fold cross validation was
performed: the data were randomly split into 5 equally sized subsets. For each subset S, the other four
subsets were used to train high precision polynomials of degree 8 through 20, with subset S being held
back as test data. The mean square error of the test data was calculated and compared to the mean
square error of training data for the same model. In other words, the estimated prediction error of a
model when generalized to unseen data was compared to the training error of the model. A model was
considered validated if
11
1. the residuals of the test data were approximately normally distributed (Figure 7); and
2. the tradeoff between high r2 (denoting possible overfitting to the data) and low generalisation error
(denoting possible underfitting to the data) was optimal (Figure 6).
Figure 7. Residual distribution for the validated model. Residuals are the squared differences
between data values and predicted values for that age.
We tested for bimodal volume distributions that would suggest distinct PCOS and non-PCOS sub-
populations by analysis of model residuals for age ranges up to 10 years, 10 – 30 years, and above 30
years. Normally-distributed residuals for log-adjusted values correspond with skew-normal population
volumes (i.e. a single population with PCOS and non-PCOS volumes forming a smooth continuum of
values). Significant variances from normality provide evidence for a distinct PCOS sub-population.
The validated model was also assessed against the Rotterdam criteria for PCOS [7, 8] by censoring
all values above the 10 mL discriminatory cutoff volume, re-fitting the model, and comparing peak ages
and volumes.
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